Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.34 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL850986 | 1.00 | TSHR (0.52) | TSHREPHX1ALDH1A1LMNAPAOX | |
| SCHEMBL19774665 | 1.00 | TSHR (0.52) | TSHREPHX1ALDH1A1LMNAPAOX | |
| SCHEMBL18317102 | 1.00 | TSHR (0.52) | TSHREPHX1ALDH1A1LMNAPAOX | |
| SCHEMBL3120998 | 1.00 | TSHR (0.52) | TSHREPHX1ALDH1A1LMNAPAOX | |
| SCHEMBL3123155 | 1.00 | TSHR (0.52) | TSHREPHX1ALDH1A1LMNAPAOX | |
| SCHEMBL849557 | 1.00 | — | — | |
| SCHEMBL1454187 | 1.00 | TSHR (0.52) | TSHREPHX1ALDH1A1LMNAPAOX | |
| SCHEMBL3118059 | 1.00 | TSHR (0.52) | TSHREPHX1ALDH1A1LMNAPAOX | |
| SCHEMBL1454255 | 1.00 | TSHR (0.52) | TSHREPHX1ALDH1A1LMNAPAOX | |
| SCHEMBL826160 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910617-B2 | Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound | SANKYO COMPANY, LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20070191468-A1 | Amino alcohol compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1733724-A1 | AMINO ALCOHOL COMPOUND | Sankyo Company, Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191468-A1 | Amino alcohol compound | ADH1A, ADH1C, BCAT1 | TSHR 1558/4885EPHX1 3367/4885ALDH1A1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.